Surrogate Endpoint For Drug-Eluting Stent Trials Hotly Contested AT TCT
This article was originally published in The Gray Sheet
Executive Summary
FDA, industry and academia should pool data to determine whether late lumen loss is a viable surrogate endpoint for drug-eluting stent trials, according to CDRH Division of Cardiovascular Devices Director Bram Zuckerman, MD
You may also be interested in...
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study
Angiographic Surrogates Gaining Importance For DES Trials – CDRH’s Boam
Surrogate angiographic endpoints are important to maintaining manageable enrollment numbers in drug-eluting stent clinical trials, according to FDA's lead interventional cardiology device reviewer